Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -24.94% is 84% above its 5-year average of -152.11%, near the high end of its 5-year range (-438.22%–-24.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.84% above its 12-month average of -31.51%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -7.01%.
RETURN ON ASSETS (ROA)
-24.94%
RETURN ON ASSETS (ROA) AVG TTM
-31.51%
RETURN ON ASSETS (ROA) AVG 3Y
-135.72%
RETURN ON ASSETS (ROA) AVG 5Y
-152.11%
RETURN ON ASSETS (ROA) AVG 10Y
-101.92%
RETURN ON ASSETS (ROA) AVG 15Y
-44.26%
RETURN ON ASSETS (ROA) AVG 20Y
-53.47%
CURRENT VS TTM AVG
+20.84%
CURRENT VS 3Y AVG
+81.62%
CURRENT VS 5Y AVG
+83.60%
CURRENT VS 10Y AVG
+75.53%
CURRENT VS 15Y AVG
+43.65%
CURRENT VS 20Y AVG
+53.36%
SECTOR MEDIAN · HEALTHCARE
-30.65%
median of 735 covered companies
CURRENT VS SECTOR MEDIAN
+18.63%
vs the sector median at left
Benitec Biopharma Inc.
Market Cap
$304.21M
Return on Assets (ROA)
-24.94%
TTM Avg
-31.51%
3Y Avg
-135.72%
5Y Avg
-152.11%
Market Cap
$295.55M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$308.22M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
Market Cap
$287.88M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$288.33M
Return on Assets (ROA)
-17.87%
TTM Avg
-36.13%
3Y Avg
-48.35%
5Y Avg
-41.88%
Market Cap
$288.21M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$286.75M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$282.68M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$285.37M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $304.21M | -24.94% | -31.51% | -135.72% | -152.11% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | -104.42% | -76.93% | -55.08% | -54.19% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.22M | -96.57% | -96.57% | -96.57% | -96.57% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.88M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.33M | -17.87% | -36.13% | -48.35% | -41.88% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.21M | -35.03% | -13.04% | -43.14% | -55.84% |
| Standard BioTools Inc. (LAB)vs › | $286.75M | -13.93% | -17.93% | -26.92% | -24.25% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | -26.24% | -12.09% | -27.60% | -33.24% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | -128.66% | -214.31% | -145.75% | -133.94% |
| C4 Therapeutics, Inc. (CCCC)vs › | $319.54M | -28.22% | -29.68% | -31.08% | -26.24% |
ROA
-24.9%
ROE
-25.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -24.94% |
| 2025-06-30 | -38.07% |
| 2024-06-30 | -41.66% |
| 2023-06-30 | -438.22% |
| 2022-06-30 | -304.84% |
| 2021-06-30 | -64.93% |
| 2020-06-30 | -70.45% |
| 2019-06-30 | 13.56% |
| 2018-06-30 | -57.47% |
| 2017-06-30 | -24.63% |
| 2016-06-30 | -69.52% |
| 2015-06-30 | -26.00% |
| 2014-06-30 | -28.58% |
| 2013-06-30 | -12.29% |
| 2012-06-30 | -127.27% |
| 2011-06-30 | -47.38% |
| 2010-06-30 | -466.12% |
| 2009-06-30 | -112.60% |
| 2008-06-30 | -128.03% |
| 2007-06-30 | -48.70% |
| 2006-06-30 | -337.91% |
| 2005-06-30 | 0.00% |
| 2004-06-30 | 0.00% |
